ArticleJournal of cachexia, sarcopenia and muscle2025
Pathways Contributing to Chemotherapy-Induced Myotoxicity Are Attenuated by EPA + DHA in a Clinically Relevant Model of Colorectal Cancer.
Article in Journal of cachexia, sarcopenia and muscle, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Dynamic postoperative trajectory of osteosarcopenia predicts the long-term outcomes in colorectal cancer.Surgery today · 2026Article
- Pathways Contributing to Chemotherapy-Induced Myotoxicity Are Attenuated by EPA + DHA in a Clinically Relevant Model of Colorectal Cancer.Journal of cachexia, sarcopenia and muscle · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundSkeletal muscle loss is a well-recognized consequence of cancer, and chemotherapy exacerbates myotoxicity through multiple mechanisms. Retaining muscle mass improves tumour response to therapies and tolerance to chemotherapy; hence, interventions to mitigate myotoxicity warrant investigations. This study aimed to investigate the protective effects of dietary eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) provided in the form of fish oil on chemotherapy-induced myotoxicity using next-generation RNA sequencing (NGS).
methodsFischer 344 rats were fed either a standard diet (STD) for the entire study or switched to a diet containing fish oil (2.3 g/100 g of diet) when chemotherapy (irinotecan + 5-fluorouracil) was initiated. All rats received the Ward colon tumour and tumours were allowed to grow for 2 weeks. Comparisons were made between (1) tumour-bearing rats on a standard diet (TUMOUR STD), (2) tumour-bearing rats that received chemotherapy on a standard diet (CHEMO STD) and (3) tumour-bearing rats that received chemotherapy on a fish oil diet (CHEMO FO). After two cycles of chemotherapy, NGS was performed on gastrocnemius muscle. Differential expression of genes was performed using DEseq2, with a fold-change cut-off ≥ 1.5 and p value < 0.05. Ingenuity pathway analysis (IPA) was used for functional annotation, canonical pathways and upstream regulators analysis.
resultsTranscriptomic analysis revealed distinct alterations in skeletal muscle gene expression profiles. In the CHEMO STD versus TUMOUR STD comparison, 272 genes showed differential expression. Of these, 55% were upregulated and 45% were downregulated. Two cycles of chemotherapy altered genes in the pathways of proliferation of muscle cells (p < 10
conclusionChemotherapy negatively impacts processes involved in muscle homeostasis, including muscle cell proliferation and regeneration. The provision of fish oil primarily showed protective effects from pro-inflammatory mediators by downregulating genes involved in the leukocyte extravasation pathway. Our findings provide novel insights into the molecular mechanisms underlying chemotherapy-induced myotoxicity and the potential therapeutic benefits of dietary EPA + DHA to restore muscle homeostasis in cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.